Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer

Colorectal Adenocarcinoma Clinical Trial

Official title:

Phase A Phase 2 Study Evaluating Response and Biomarkers in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer Treated With Nivolumab in Combination With Relatlimab

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03642067
• Other study ID #: J18119
• Secondary ID: IRB00173537CA224
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: February 12, 2019
• Est. completion date: February 23, 2025

Study information

• Verified date: May 2024
• Source: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and clinical activity of nivolumab and relatlimab in patients with metastatic or locally advanced microsatellite stable (MSS) colorectal cancer.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 59
• Est. completion date: February 23, 2025
• Est. primary completion date: February 23, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age =18 years.

• ECOG performance status 0 or 1

• Have metastatic or locally advanced microsatellite stable (MSS) colorectal adenocarcinoma.

• Cohort A: Primary lesion has a composite PD-L1/Mucin (CPM) score = 15%.

• Cohort B: Primary lesion has a composite PD-L1/Mucin (CPM) score < 15%.

• Cohort C: Prior surgical resection of primary tumor. Prospective biomarker evaluation not required.

• Must have received at least one chemotherapy regimen.

• Patients with the presence of at least one measurable lesion using RECIST 1.1.

• Patients must have available archival tissue from the surgical resection of their primary tumor.

• Patient's acceptance of tumor biopsies.

• Life expectancy of greater than 3 months.

• Patients must have adequate organ and marrow function defined by study - specified laboratory tests.

• Documented LVEF = 50% - 6 month prior to drug administration.

• Must use acceptable form of birth control while on study.

• Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

• Known history or evidence of brain metastases. Patients with previously treated brain metastases may participate if they are stable for 4 weeks prior to beginning treatment, have no new or enlarging brain metastases, and are not using steroids for at least 1 week prior to initiation of study treatment.

• Require any antineoplastic therapy.

• History of prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, or anti-Lag-3 antibodies.

• Had chemotherapy, radiation, or steroids within 14 days prior to study treatment.

• Had any cytotoxic drug within 4 weeks prior to initiation of study treatment.

• Hypersensitivity reaction to any monoclonal antibody.

• Has uncontrolled intercurrent acute or chronic medical illness.

• Has an active known or suspected autoimmune disease.

• Has a diagnosis of immunodeficiency.

• Prior tissue or organ allograft or allogeneic bone marrow transplantation.

• Requires daily supplemental oxygen

• History of interstitial lung disease.

• Requires daily supplemental oxygen.

• Significant heart disease

• History of encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent.

• Infection with HIV or hepatitis B or C at screening.

• Has an active infection.

• Unable to have blood drawn.

• Patient with uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

• Woman who are pregnant or breastfeeding.

Related Conditions & MeSH terms

• Adenocarcinoma
• Colorectal Adenocarcinoma
• Colorectal Neoplasms
• Microsatellite Stable (MSS) Colorectal Adenocarcinomas

Intervention

Drug:
• Nivolumab
Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
• Relatlimab
Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
• Nivolumab
Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
• Relatlimab
Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).

Locations

Country	Name	City	State
United States	Sidney Kimmel Comprehensive Cancer Center	Baltimore	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Bristol-Myers Squibb

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cohort A/B: Objective response rate (ORR)	The proportion of subjects with partial response (PR) or complete response (CR) according to RECIST 1.1.	4 years
Primary	Cohort C: Objective response rate (ORR)	The proportion of subjects with partial response (PR) or complete response (CR) according to RECIST 1.1.	4 years
Secondary	Number of participants experiencing study drug-related toxicities	Number of participants experiencing study drug-related adverse events Grade 3 or higher as defined by CTCAE v5.0	4 years